Shanghai Pharmaceuticals Holding Co Ltd 2024 SR
The report details SPH's ESG performance for 2024, highlighting its climb to 411th on the Fortune Global 500. Key achievements include the inauguration of the Shanghai Biomedical Frontier Industry Innovation Center (SH INNO) and the establishment of Shanghai Kangjiansheng Cell Technology to advance cell and gene therapy. The company operated 11 national-level Green Factories and invested CNY 2,818 million in R&D. SPH also focused on rare disease treatments, supplying medicines to 150,000 patients. Philanthropic contributions totaled CNY 21,009,900, supporting rural revitalization and disaster relief.
Company: Shanghai Pharmaceuticals Holding Co Ltd
Sector: Health Care
Country: China
Year: 2024
Type: SR
Pages: 83
Shanghai Pharmaceuticals Holding Co Ltd
Sustainability Report And ESG Report
The report details SPH's ESG performance for 2024, highlighting its climb to 411th on the Fortune Global 500. Key achievements include the inauguration of the Shanghai Biomedical Frontier Industry Innovation Center (SH INNO) and the establishment of Shanghai Kangjiansheng Cell Technology to advance cell and gene therapy. The company operated 11 national-level Green Factories and invested CNY 2,818 million in R&D. SPH also focused on rare disease treatments, supplying medicines to 150,000 patients. Philanthropic contributions totaled CNY 21,009,900, supporting rural revitalization and disaster relief.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Workplace Fatalities
Employees